CRISPR in the Clinic: How Gene Editing Made the Leap from Lab to Patient in 2026
The Historic Milestone: Baby KJ and the Six-Month Miracle
In what researchers are calling a historic milestone for genetic medicine, a team of physicians and scientists at Children Hospital of Philadelphia (CHOP) and the University of Pennsylvania successfully treated an infant with a personalized CRISPR gene editing therapy, developed and delivered in just six months. The case, published in the New England Journal of Medicine in May 2025 and celebrated at its one-year anniversary in 2026, represents the first time a patient has been treated with an on-demand, personalized in vivo CRISPR therapy.
The patient, known as Baby KJ, was born with carbamoyl phosphate synthetase I (CPS1) deficiency, a rare and life-threatening metabolic disorder that prevents the body from processing ammonia. Without treatment, the condition causes irreversible brain damage and is often fatal in infancy. Standard treatments, including dietary management and ammonia-scavenging medications, offered limited help. The team, led by researchers from the Innovative Genomics Institute (IGI) at UC Berkeley, designed a CRISPR therapy specifically for KJ unique mutation, received FDA approval, and administered the treatment all within six months of diagnosis.
This was a remarkable team effort, said Jennifer Doudna, founder of the IGI and recipient of the 2020 Nobel Prize in Chemistry for her role in the development of CRISPR gene editing. Years and years of progress in gene editing and collaboration between researchers and clinicians made this moment possible.
From N-of-1 to a New Paradigm
The significance of the KJ case extends far beyond a single patient. It demonstrates that personalized CRISPR therapies can be developed rapidly enough to treat acute, life-threatening genetic conditions a proposition that many in the field considered aspirational at best just a few years ago.
Traditional drug development follows a one-size-fits-all model: identify a disease, develop a drug, test it in thousands of patients, and seek approval for a broad indication. This model works well for common diseases but fails utterly for rare genetic disorders, especially those caused by unique mutations that affect only a handful of patients or even a single individual worldwide.
The KJ case establishes a new paradigm: identify a patient unique mutation, design a CRISPR guide RNA specific to that mutation, package it in lipid nanoparticles (LNPs), obtain regulatory approval, and deliver the therapy all on a compressed timeline measured in months, not years. The treatment was administered via IV infusion, with the LNPs delivering the CRISPR machinery directly to liver cells, where CPS1 is primarily expressed.
The Broader CRISPR Clinical Trial Landscape in 2026
Beyond personalized therapies, the CRISPR clinical trial landscape has expanded dramatically. The Innovative Genomics Institute 2026 update catalogs dozens of active trials across multiple disease categories:
Sickle Cell Disease and Beta-Thalassemia: The approval of Casgevy (exagamglogene autotemcel) in late 2023 marked CRISPR first regulatory approval. By 2026, thousands of patients have been treated, and real-world data is confirming the durability of the therapy. Victoria Gray, the first patient to receive CRISPR-based gene therapy for sickle cell disease, has become a public advocate, sharing how the treatment transformed every part of her life.
Cancer Immunotherapy: CRISPR is increasingly being used to engineer CAR-T cells with enhanced tumor-killing capabilities. While CAR-T has been most successful against blood cancers like leukemia, researchers are now using CRISPR screens to identify new targets and design therapies that can tackle solid tumors the next frontier in cancer immunotherapy.
In Vivo Editing for Genetic Diseases: Beyond CPS1 deficiency, in vivo CRISPR therapies are being developed for transthyretin amyloidosis, hereditary angioedema, and several forms of inherited blindness. The ability to edit genes directly inside the body, rather than removing cells, editing them in a lab, and reinfusing them, represents a major advance in accessibility and scalability.
Cardiovascular Disease: Verve Therapeutics is pioneering CRISPR base editing to permanently lower LDL cholesterol by inactivating the PCSK9 gene in the liver. Early clinical data has shown durable cholesterol reductions with a single infusion, potentially offering a one-and-done alternative to daily statins or biweekly PCSK9 inhibitor injections.
Challenges and Cautions: The Road Ahead
The CRISPR field has not been without setbacks. In 2024, the first death associated with a CRISPR clinical trial was reported in a patient with Duchenne muscular dystrophy treated by the nonprofit Cure Rare Disease. The case underscored the profound risks of pioneering therapies, particularly when delivered systemically at high doses.
Off-target effects when CRISPR edits DNA at unintended locations remain a concern for all gene editing approaches. While newer technologies like base editing and prime editing offer greater precision, the possibility of unintended genetic changes, including those that could increase cancer risk, requires long-term monitoring of all treated patients.
Cost and access present another major challenge. Casgevy, the first approved CRISPR therapy, carries a list price of $2.2 million per patient in the United States. While this compares favorably to the lifetime cost of managing severe sickle cell disease, it places the therapy out of reach for many patients in low- and middle-income countries where the disease burden is highest.
The regulatory framework is also evolving. The FDA has shown flexibility in the KJ case, approving a therapy designed for a single patient. But how to scale that approach to the thousands of rare disease patients who could benefit from personalized CRISPR therapies while maintaining safety standards is a question regulators are actively grappling with.
What Comes Next: 2026 and Beyond
Several developments are likely to define the next phase of CRISPR medicine:
Expansion of personalized therapy programs: The KJ case has inspired multiple academic medical centers to establish rapid-response programs capable of developing customized CRISPR therapies for patients with urgent genetic conditions. The goal is to create a systematic framework rather than a one-off heroic effort.
Improved delivery technology: Lipid nanoparticles work well for liver-targeted therapies but struggle to reach other organs. New delivery platforms, including engineered virus-like particles and targeted nanoparticles, are being developed to expand the range of treatable tissues.
Next-generation editing tools: Base editing (which chemically converts one DNA letter to another without cutting both strands) and prime editing (which can insert, delete, or replace DNA sequences with greater precision) are moving toward clinical trials, promising safer and more versatile gene correction.
Durable data from treated patients: As the earliest CRISPR-treated patients pass the five-year mark, long-term safety and efficacy data will either validate the approach or reveal unexpected complications. So far, the signals have been encouraging.
Conclusion: The Promise Becomes Reality
The CRISPR story is no longer about potential it is about patients. From Victoria Gray to Baby KJ, real people are living healthier lives because of gene editing technology that did not exist when they were born. The field has moved from proof-of-concept to clinical reality faster than almost anyone predicted.
The challenges are real: safety, cost, access, and the ethical questions raised by the ability to rewrite the human genome. But the trajectory is unmistakable. CRISPR is in the clinic, and it is here to stay. The question is no longer whether gene editing will transform medicine, but how quickly and for how many.
Published May 31, 2026
